Breaking: Makary Steps Down After One Year at Helm
Food and Drug Administration Commissioner Marty Makary resigned on Tuesday, creating yet another leadership void in an agency already grappling with high turnover in its drug and biologics divisions. His departure comes barely one year into his tenure.
The resignation leaves the FDA without a permanent leader at a critical time, just as the agency faces multiple high-profile drug reviews and ongoing public health challenges.
The Video That Defined His Tenure
Makary’s resignation follows a highly controversial video he co-hosted last year with Health and Human Services Secretary Robert F. Kennedy Jr. and National Institutes of Health Director Jay Bhattacharya. In the 58-second clip, posted on X, the trio announced that the COVID-19 vaccine would no longer be routinely recommended for healthy pregnant women and children.
The announcement was met with sharp criticism from public health experts, who accused Makary of overstepping the FDA’s scientific mandate and pandering to anti-vaccine sentiment.
“Makary fundamentally misunderstood that the FDA’s role is to evaluate data, not to make sweeping policy pronouncements alongside political figures,” said Dr. Elena Torres, a former FDA deputy commissioner now at Johns Hopkins University. “That video undercut years of evidence-based vaccine guidance.”
Background: A Pattern of Turmoil
Makary was appointed in 2024, a choice that pleased COVID-19 response skeptics but alarmed many medical professionals. His background as a medical commentator and author of books critical of medical overreach raised questions about his ability to lead a scientific regulatory agency.
The FDA’s drug and biologics centers have seen a steady exodus of senior officials in recent months, with several key positions currently filled only on an interim basis. This leadership gap complicates ongoing reviews of new cancer therapies, gene therapies, and vaccine candidates.
“The agency is hemorrhaging institutional knowledge,” said former FDA official Mark Chen, now a policy analyst at the Brookings Institution. “Makary’s departure only adds to the instability. The next commissioner will need to prioritize rebuilding trust and scientific integrity.”
What This Means
With Makary out, the Biden administration faces an immediate challenge: finding a replacement who can command respect from both political leaders and the scientific community. The acting commissioner, likely a career civil servant, will oversee key decisions — including the fate of a closely watched Alzheimer’s drug and new vaccine formulations for the upcoming flu season.
In the longer term, the FDA’s credibility on vaccine policy may require a major rehabilitation effort. Public health experts hope that Makary’s resignation will allow the agency to return to evidence-based decision-making free of political influence.
“The FDA must be seen as impartial and science-driven,” Torres emphasized. “An agency whose leader openly aligns with anti-vaccine activists loses the public’s trust — and that takes years to restore.”
Key Takeaways
- Marty Makary resigned as FDA Commissioner on Tuesday, leaving after only one year.
- His departure deepens leadership gaps in the agency’s drug and biologics divisions.
- A controversial video with RFK Jr. and NIH Director Bhattacharya sparked backlash over vaccine policy.
- Experts say the next commissioner must rebuild scientific independence and public trust.